Store
The World Market for Vaccines, 2024
Publication Date: February 22, 2024
Tags: COVID-19, Endemic, Hepatitis, Hib, HPV, Immunization, Influenza, Meningitis, Pandemic Vaccines, Pertussis, Pharmaceuticals, Pneumococcal, Polio, Rotavirus, RSV, Shingles, Tetanus, Vaccines
Pages: 200
SKU: 24-012
Vaccines are a cornerstone of preventive medicine, offering long-term or permanent immunity against diseases. They have been instrumental in near-eliminating many deadly diseases, making vaccination one of the greatest public health achievements of the 20th century. Kalorama Information’s latest report, The World Market for Vaccines, 2024, provides a comprehensive analysis of adult and pediatric preventative vaccines, including market forecasts, company market share data, and expert market estimates for different vaccine categories.
Stay informed about the latest trends and developments in the global vaccines market with The World Market for Vaccines, 2024. Order now to receive valuable insights that can help drive your business forward!
Key Highlights:
- Market Analysis: Explore the market trends for human vaccines used to prevent various diseases, including commercialized vaccines and developmental vaccines for vaccine-preventable diseases.
- Emerging Vaccines: Learn about selected emerging vaccines in development and their potential impact on the market.
- Vaccine Categories: Gain insights into key vaccine categories, including combinations (tetanus, pertussis, Hib, Hepatitis, polio), HPV, influenza, meningitis, pandemic vaccines/COVID-19, pneumococcal, rotavirus, RSV, shingles, and others.
- Company Profiles: Understand the market landscape with profiles of key companies involved in vaccine development and distribution.
Scope and Methodology:
The report covers human vaccines used to prevent various diseases, focusing on commercialized vaccines and developmental vaccines for vaccine-preventable diseases. It also includes a discussion of selected emerging vaccines and covers the COVID-19 vaccine market landscape. Sales estimates are provided for each market segment, representing global revenues expressed in current dollars, with estimates for 2023 and forecasts for 2028. Data was gathered from a variety of sources, including company reports, government documents, trade journals, and interviews with industry experts.
Table: Global Market for Pediatric Preventive Vaccines, by Type, 2023–2028 (in millions $)
| Pediatric Vaccines | 2023 | 2028 | CAGR 2023-2028 |
| Hepatitis | $XX Million | $XX Million | XX% |
| Pediatric Routine (Combinations, HiB, MMR, Polio, Varicella) | $XX Million | $XX Million | XX% |
| Meningitis | $XX Million | $XX Million | XX% |
| Pneumococcal | $XX Million | $XX Million | XX% |
| Rotavirus | $XX Million | $XX Million | XX% |
| Influenza | $XX Million | $XX Million | XX% |
| HPV | $XX Million | $XX Million | XX% |
| Pandemic vaccines/COVID-19 | $XX Million | $XX Million | XX% |
| Others | $XX Million | $XX Million | XX% |
| Total | $XX Million | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter 1: Executive Summary
The Global Vaccines Industry
Scope and Methodology
Market Estimates and Forecasts
- Figure 1-1: Global Vaccine Market (Non-COVID Vaccine Market; COVID Vaccine Market), 2023–2028 ($M)
- Figure 1-2: Regional Non-COVID vs COVID Vaccine Markets, 2018-2028 ($)
Competitive Analysis
Chapter 2: Introduction to Vaccines
Introduction
- Table 2-1: Global Reported Cases of Vaccine Preventable Diseases, 2000 vs. 2022
- Figure 2-1: CDC Infographic: Global Impact of Vaccines in Reducing Vaccine-Preventable Disease Morbidity and Mortality
A Brief History: The Development of Vaccines
The Human Immune System
Vaccine Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
- Figure 2-2: Attenuated Virus Production
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccines
Messenger RNA Vaccines
Recombinant Vector Vaccines
Classification of Vaccines
Vaccine Approval Process
- Figure 2-3: Global Vaccine Sales by Region, 2023
FDA EUA Approval
World Health Organization Prequalified Vaccines
- Table 2-3: WHO Prequalified BCG Vaccines
- Table 2-4: WHO Prequalified Cholera Vaccines
- Table 2-5: WHO Prequalified Diphtheria-Tetanus Vaccines
- Table 2-6: WHO Prequalified Diphtheria-Tetanus-Pertussis Vaccines
- Table 2-7: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hemophilus influenzae type b Vaccines
- Table 2-8: WHO Prequalified Diphtheria-Tetanus-Pertussis and Hepatitis B Vaccines
- Table 2-9: WHO Prequalified Diphtheria-Tetanus-Pertussis-Hepatitis B-Hemophilus influenzae type b Vaccines
- Table 2-10: WHO Prequalified Hemophilus influenzae type b Vaccines
- Table 2-11: WHO Prequalified Hepatitis A Vaccines
- Table 2-12: WHO Prequalified Hepatitis B Vaccines
- Table 2-13: WHO Prequalified Human Papillomavirus Vaccines
- Table 2-14: WHO Prequalified Influenza Vaccines
- Table 2-15: WHO Prequalified Japanese Encephalitis Vaccines
- Table 2-16: WHO Prequalified Measles Vaccines
- Table 2-17: WHO Prequalified Measles and Rubella Vaccines
- Table 2-18: WHO Prequalified Measles, Mumps and Rubella Vaccines
- Table 2-19: WHO Prequalified Meningococcal A Vaccines
- Table 2-20: WHO Prequalified Pneumococcal Vaccines
- Table 2-21: WHO Prequalified Polio Vaccines
- Table 2-22: WHO Prequalified Rabies Vaccines
- Table 2-23: WHO Prequalified Rotavirus Vaccines
- Table 2-24: WHO Prequalified Rubella Vaccines
- Table 2-25: WHO Prequalified Tetanus Toxoid Vaccines
- Table 2-26: WHO Prequalified Typhoid Vaccines
- Table 2-27: WHO Prequalified Varicella Vaccine
- Table 2-28: WHO Prequalified Yellow Fever Vaccines
- Table 2-29: WHO Prequalified Other Vaccines
Pandemics
HIN1 Pandemic of 2009/2010
Coronavirus Pandemic
- Figure 2-4: Leading COVID-19 Vaccines: Supplied Dose Estimates
Ebola Epidemics
Manufacturing Incentives
Synthetic Vaccines
Artificial Intelligence Development
Chapter 3: Pediatric Preventative Vaccines
Introduction
- Table 3-1: Immunization Rates for Vaccines Recommended by the WHO, 2022
Childhood Immunization in the United States
Childhood Immunization Rates
Challenges to the Vaccine Delivery System
Recommended Childhood Immunization Schedule
- Figure 3-1: CDC Recommended Child and Adolescent Immunization Schedule for Ages 18 Years or Younger, United States, 2024
- Figure 3-2: CDC Recommended Child and Adolescent Immunization Schedule by Medical Indication, United States, 2024
State Immunization Recommendations
- Figure 3-3: Exemptions Permitted for State Childcare and School (Grades PreK-12) Immunization Requirements, United States, March 2023
COVID-19 Vaccination Schedule
United Nations Initiatives
Pediatric Vaccine Markets
- Table 3-2: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023–2028 ($M)
- Figure 3-4: Global Market for Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023–2028 (%)
- Figure 3-5: Market Share of Pediatric Preventive Vaccines, by Type (Hepatitis, Pediatric Routine [HiB, MMR, Combinations, Polio, Varicella], Meningitis, Pneumococcal Disease, Rotavirus, Influenza, HPV, Pandemic, Others), 2023 (%)
Competitive Summary
- Table 3-3: Major Manufacturers’ Shares of the Global Pediatric Preventative Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
- Figure 3-6: Global Pediatric Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Merck, Moderna, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023, (%)
Chapter 4: Adult Preventative Vaccines
Introduction
Recommended Adult Immunizations
- Figure 4-1: CDC Recommended Immunization Schedule: Adults, 19 years and over
Global Influenza Surveillance Program
U.S. Surveillance
- Table: 4-1: U.S. Influenza Vaccine Effectiveness, 2004–2023 (%)
- Figure 4-2: U.S. Influenza Vaccine Effectiveness, by Season, 2009-2023, (%)
WHO International Health Regulations
Adult Preventive Vaccine Markets
- Table 4-2: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023–2028 ($M)
- Figure 4-3: Global Market for Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other), 2023–2028 (%)
- Figure 4-4: Market Share of Adult Preventive Vaccines, by Type (Hepatitis, HPV, Influenza, Pneumococcal, Tetanus and combinations, Shingles, Pandemic, Travel & Other) 2023 (%)
Market: Generating 26% of Total Adult Non-COVID Vaccine Sales
- Figure 4-5: U.S. Seasonal Influenza Vaccination, by Age Group and Season, 2010-2023 (%)
- Figure 4-6: U.S. Seasonal Influenza Vaccination Coverage and HP 2020 Target – Total Population – Seasons, 2010-2023 (%)
Influenza
- Figure 4-7: Estimated U.S. Flu Burden, by Season 2010-2023
- Table 4-3: Estimated Number of Influenza Illnesses Averted by Vaccination, by Age Group – United States, 2022-2023 Influenza Season
- Table 4-4: Estimated Number of Influenza Medical Visits Averted by Vaccination, by Age Group – United States, 2022-2023 Influenza Season
- Table 4-5: Estimated Number and Fraction of Influenza Hospitalizations Averted by Vaccination, by Age Group – United States, 2022-2023 Influenza Season
- Table 4-6: Estimated Number of Influenza Deaths Averted by Vaccination, by Age Group – United States, 2022-2023 Influenza Season
- Figure 4-8: Estimated U.S. Flu Burden Prevented by Vaccination (Deaths, Hospitalizations, Medical Visits, Symptomatic Illness), 2010-2023
- Table 4-7: WHO Pandemic Classification Schedule
Competitive Summary
- Table 4-8: Major Manufacturers’ Shares of the Global Adult Preventative Vaccine Market, by Company (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%, $M)
- Figure 4-9: Global Adult Preventative Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, Johnson & Johnson, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinovac, Others), 2023 (%)
Chapter 5: Total Vaccines Market
Trends Driving the Vaccines Market
- Figure 5-1: Sales Growth of Vaccines vs. Pharmaceuticals, 2015-2025
Market Size and Forecast
- Table 5-1: Total Global Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023–2028 ($M)
- Figure 5-2: Total World Market for Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]),, 2023-2028 (Pediatric, Adult) (SM)
- Figure 5-3: Total World Vaccine Market, Non-COVID and COVID Vaccine, 2023-2028 ($M)
Pediatric Vaccines
Adult Vaccines
- Figure 5-4: Global Preventive Vaccine Market, by Broad Segment (Pediatric, Adult), Trend 2018–2028 ($M)
COVID-19 Market Size Estimates and Forecast
- Table 5-2: Global COVID-19 Vaccine Market Cumulative Value, 2020-2023 ($M)
- Figure 5-5: Global COVID-19 Vaccine by Unit Volume, Cumulative 2020-2023, Estimated Distribution by Country (Australia, Brazil, Canada, China, European Union, India, Japan, Russia, South Africa, South Korea, United States, Other Countries)
Vaccine Sales by Region
Rest of World
- Table 5-3: Total ROW Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023–2028 ($M)
United States
- Table 5-4: Total U.S. Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, RSV, Shingles, Others [travel, endemic, etc.]), 2023–2028 ($M)
Europe
- Table 5-5: Total Europe Market for Preventive Vaccines, by Type (Combinations [tetanus, pertussis, Hib, Hepatitis, polio], Hepatitis, HPV, Influenza, Meningitis, Pandemic vaccines/COVID-19, Pneumococcal, Rotavirus, Shingles, Others [travel, endemic, etc.]), 2023–2028 ($M)
Vaccine Market Competitors
- Table 5-6: Major Manufacturers’ Shares of the Global Vaccine Market, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%, $M)
- Figure 5-6: Global Vaccines Market Share, by Leading Competitors (AstraZeneca, BioNTech, CSL, GlaxoSmithKline, J&J/Janssen, Merck, Moderna, Novavax, Pfizer, Sanofi Pasteur, Sinova, Other), 2023 (%)
Vaccine Industry News
Vaccines in Development
COVID-19 Vaccine Development
- Figure 5-7: Regional Distribution of COVID-19 Vaccine Development, by Country and Region (Australia, Brazil, Canada, China, France, Indonesia, Japan, Mexico, Middle East, Philippines, Rest of Africa, Rest of Pacific, Rest of Europe, Rest of Latin America, South Africa, South Korea, United Kingdom, United States)
- Table 5-7: Selected Vaccines in Development, 2023
Chapter 6: Company Profiles
AstraZeneca
- Table 6-1: AstraZeneca Corporate Summary
Company Summary
Products
Bavarian Nordic, A/S
- Table 6-2: Bavarian Nordic A/S Corporate Summary
Company Summary
Products
Bharat Biotech International Ltd.
- Table 6-3: Bharat Biotech Corporate Summary
Company Summary
Products
Bio Farma
- Table 6-4: Bio Farma Corporate Summary
Company Summary
Products
BioNTech SE
- Table 6-5: BioNTech Corporate Summary
Company Summary
Products
CSL Limited/Seqirus
- Table 6-6: CSL/Seqirus Corporate Summary
Company Summary
Products
Dynavax Technologies
- Table 6-7: Dynavax Technologies Corporate Summary
Company Summary
Products
Emergent BioSolutions, Inc.
- Table 6-8: Emergent BioSolutions Corporate Summary
Company Summary
Products
GlaxoSmithKline, Inc.
- Table 6-9: GlaxoSmithKline Corporate Summary
Company Summary
Products
- Table 6-10: GSK Marketed Vaccines, 2024
Inovio Pharmaceuticals, Inc.
- Table 6-11: Inovio Corporate Summary
Company Summary
Products
Johnson & Johnson/Crucell/Janssen
- Table 6-12: Johnson & Johnson Corporate Summary
Company Summary
Products
Merck & Co, Inc.
- Table 6-13: Merck Corporate Summary
Company Summary
Products
Moderna, Inc
- Table 6-14: Moderna Corporate Summary
Company Summary
Products
Novavax, Inc.
- Table 6-15: Novavax Corporate Summary
Company Summary
Products
Pfizer, Inc.
- Table 6-16: Pfizer Corporate Summary
Company Summary
Products
Sanofi Pasteur
- Table 6-17: Sanofi Pasteur Corporate Summary
Company Summary
Products
Serum Institute, Inc.
- Table 6-18: Serum Institute of India Corporate Summary
Company Summary
Products
Sinovac Biotech Ltd.
- Table 6-19: Sinovac Biotech Corporate Summary
Company Summary
Products
Soligenix, Inc.
- Table 6-20: Soligenix Corporate Summary
Company Summary
Products
Takeda Pharmaceutical Co, Ltd.
- Table 6-21: Takeda Pharmaceutical Corporate Summary
Company Summary
Products
Valneva SE
- Table 6-22: Valneva Corporate Summary
Company Summary
Products
Related products
In Vitro Diagnostic (IVD) Procedure Volumes, 2023-2028
October 22, 2023
Gain invaluable insights into the global IVD market with Kalorama Information’s comprehensive report In Vitro Diagnostic (IVD) Procedure Volumes (Chemistry, Immunoassays, Hematology, Microbiology, Histology, Point of Care), 2023-2028. This analysis provides essential data on the number of IVD procedures, offering a gold standard for new entrants and existing marketers in the diagnostic products industry.
…
Price range: $6,000.00 through $9,000.00
Cell and Gene Therapy Funding and Deals Analysis, 2021-2023
December 8, 2023
Explore the dynamic world of cell and gene therapy deal-making with Kalorama Information’s comprehensive report, Cell and Gene Therapy Funding and Deals Analysis: Financings, Partnering, M&A, Tech Transfers, IPOs/SPACs, Other Deals, 2021-2023. This report tracks the deal-making activities in cell and gene therapy since 2021, providing insightful graphs of quarterly trends from 2021-2023 and detailing…
Price range: $5,000.00 through $7,500.00
Histology and Cytology IVD Market Update, 2024
May 21, 2024
Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.
Histology and Cytology IVD Market Update, 2024 provides an in-depth competitive analysis…
Price range: $5,000.00 through $7,875.00
